Status:
COMPLETED
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
Lead Sponsor:
Myriad Genetic Laboratories, Inc.
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
This registry is intended to measure the impact of Prolaris® testing on therapeutic decisions when added to standard clinical-pathological parameters in men with newly diagnosed prostate cancer.
Eligibility Criteria
Inclusion
- Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics.
- Clinically localized (no evidence on clinical or imaging studies of advanced disease.
- No hormonal therapy including LHRH agonist or antagonist, anti-androgen, 5-alpha reductase inhibitor, estrogens or exogenous androgens, when applicable.
- Sufficient amount of tissue remains from biopsy to perform genomic testing.
Exclusion
- Patients with known history of hypogonadism will be excluded from the registry
Key Trial Info
Start Date :
May 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 8 2015
Estimated Enrollment :
274 Patients enrolled
Trial Details
Trial ID
NCT02209584
Start Date
May 1 2014
End Date
December 8 2015
Last Update
September 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington
Seattle, Washington, United States, 98195